Modelling the concentration of anti-SARS-CoV-2 immunoglobulin G in intravenous immunoglobulin product batches.
PLoS One
; 16(11): e0259731, 2021.
Article
en En
| MEDLINE
| ID: mdl-34843493
ABSTRACT
BACKGROUND:
Plasma-derived intravenous immunoglobulin (IVIg) products contain a dynamic spectrum of immunoglobulin (Ig) G reactivities reflective of the donor population from which they are derived. We sought to model the concentration of anti-severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) IgG which could be expected in future plasma pool and final-product batches of CSL Behring's immunoglobulin product Privigen. STUDY DESIGN ANDMETHODS:
Data was extracted from accessible databases, including the incidence of coronavirus disease 2019 and SARS-CoV-2 vaccination status, antibody titre in convalescent and vaccinated groups and antibody half-life. Together, these parameters were used to create an integrated mathematical model that could be used to predict anti-SARS-CoV-2 antibody levels in future IVIg preparations.RESULTS:
We predict that anti-SARS-CoV-2 IgG concentration will peak in batches produced in mid-October 2021, containing levels in the vicinity of 190-fold that of the mean convalescent (unvaccinated) plasma concentration. An elevated concentration (approximately 35-fold convalescent plasma) is anticipated to be retained in batches produced well into 2022. Measurement of several Privigen batches using the Phadia™ EliA™ SARS-CoV-2-Sp1 IgG binding assay confirmed the early phase of this model.CONCLUSION:
The work presented in this paper may have important implications for physicians and patients who use Privigen for indicated diseases.
Texto completo:
1
Banco de datos:
MEDLINE
Asunto principal:
Inmunoglobulina G
/
Inmunoglobulinas Intravenosas
/
SARS-CoV-2
/
COVID-19
/
Modelos Biológicos
/
Anticuerpos Antivirales
Tipo de estudio:
Prognostic_studies
Límite:
Adult
/
Humans
/
Middle aged
Idioma:
En
Año:
2021
Tipo del documento:
Article